» Articles » PMID: 33212187

Vesicular ATP Release from Hepatocytes Plays a Role in the Progression of Nonalcoholic Steatohepatitis

Overview
Publisher Elsevier
Date 2020 Nov 19
PMID 33212187
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic steatohepatitis (NASH) is becoming a growing public health problem along with the increase of metabolic syndrome worldwide. Extracellular nucleotides are known to serve as a danger signal by initiating purinergic signaling in many inflammatory disorders, although the role of purinergic signaling in the progression of NASH remains to be clarified. Vesicular nucleotide transporter (VNUT) is a key molecule responsible for vesicular ATP release to initiate purinergic signaling. Here, we studied the role of VNUT in the progression of nonalcoholic steatohepatitis. VNUT was expressed in mouse hepatocytes and associated, at least in part, with apolipoprotein B (apoB)-containing vesicles. High glucose stimulation evoked release of appreciable amount of ATP from hepatocytes, which disappeared in hepatocytes of Vnut knockout (Vnut) mice. Glucose treatment also stimulated triglyceride secretion from hepatocytes, which was inhibited by PPADS and MRS211, antagonists of P2Y receptors, and clodronate, a VNUT inhibitor, and was significantly reduced in Vnut mice. In vivo, postprandial secretion of triglyceride from hepatocytes was observed, while the serum triglyceride level was significantly reduced in Vnut mice. On a high-fat diet, the liver of wild type mice exhibited severe inflammation, fibrosis, and macrophage infiltration, which is similar to NASH in humans, while this NASH pathology was not observed in Vnut mice. These results suggest that VNUT-mediated vesicular ATP release regulates triglyceride secretion and involves in chronic inflammation in hepatocytes. Since blockade of vesicular ATP release protects against progression of steatohepatitis, VNUT may be a pharmacological target for NASH.

Citing Articles

The Role of Solute Carrier Family Transporters in Hepatic Steatosis and Hepatic Fibrosis.

Zhang C, Yang X, Xue Y, Li H, Zeng C, Chen M J Clin Transl Hepatol. 2025; 13(3):233-252.

PMID: 40078199 PMC: 11894391. DOI: 10.14218/JCTH.2024.00348.


Favorable inhibitory effect of clodronate on hepatic steatosis in short bowel syndrome model rats.

Tsuruno Y, Nagano A, Sugita K, Onishi S, Tabata Y, Kedoin C Pediatr Surg Int. 2024; 40(1):307.

PMID: 39537943 PMC: 11561034. DOI: 10.1007/s00383-024-05858-y.


RANK-RANKL-OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives.

Monti F, Perazza F, Leoni L, Stefanini B, Ferri S, Tovoli F Int J Mol Sci. 2024; 25(17).

PMID: 39273141 PMC: 11395242. DOI: 10.3390/ijms25179193.


Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease.

Tokumaru T, Apolinario M, Shimizu N, Umeda R, Honda K, Shikano K Sci Rep. 2024; 14(1):7813.

PMID: 38565862 PMC: 10987586. DOI: 10.1038/s41598-024-58043-5.


A purinergic mechanism underlying metformin regulation of hyperglycemia.

Senfeld J, Peng Q, Shi Y, Qian S, Shen J iScience. 2023; 26(6):106898.

PMID: 37378329 PMC: 10291329. DOI: 10.1016/j.isci.2023.106898.